Category: Include on Menu
-
U.S. Stock Futures Edge Lower Amid Trump Tariff Uncertainty; Nvidia Earnings Loom: Dow Jones, S&P, Nasdaq, Wall Street
U.S. equity futures moved modestly lower on Monday as investors assessed the fallout from the Supreme Court’s ruling against President Donald Trump’s emergency tariffs, while attention turned toward upcoming earnings from semiconductor heavyweight Nvidia later this week. As of 05:50 ET, Dow Jones futures were down 110 points, or 0.2%, S&P 500 futures declined 16…
-
U.S. Silver Mining Stocks Climb as Metal Prices Reach Two-Week Peak
Shares of U.S.-listed silver mining companies moved higher in premarket trading on Monday after silver prices rallied to their strongest level in more than two weeks. Spot silver advanced 2.6% to $86.73 per ounce, supported by a weaker U.S. dollar following a Supreme Court ruling that challenged President Donald Trump’s tariff measures. Among individual miners,…
-
Domino’s Pizza Shares Rise After Revenue Beat and Strong Sales Growth
Domino’s Pizza Inc. (NASDAQ:DPZ) reported fourth-quarter results on Monday that topped revenue forecasts but narrowly missed earnings expectations, with shares climbing following the announcement. The stock rose 6.4% after the release and gained 4.8% in premarket trading to $403.04, supported by stronger-than-expected U.S. same-store sales performance. The pizza chain posted adjusted earnings per share of…
-
Merck Plans Separate Cancer Division as Keytruda Patent Expiry Approaches
Merck (NYSE:MRK) announced Monday that it will reorganize its human health operations into two distinct units, establishing a dedicated oncology division centered on its flagship cancer therapy Keytruda, while placing its remaining medicines into a separate non-oncology business. The restructuring highlights the U.S. pharmaceutical company’s effort to reduce reliance on Keytruda as the drug approaches…
-
Emera Tops Fourth-Quarter Earnings Forecasts
Emera Inc. (NYSE:EMA) reported fourth-quarter adjusted earnings per share of $0.55 on Monday, surpassing analyst expectations of $0.44. The Canadian utility recorded adjusted net income of $167 million for the quarter, down from $246 million in the same period a year earlier. Shares were unchanged in after-hours trading following the announcement. The year-over-year decline in…
-
Freshpet Shares Slip Despite Earnings Beat as Revenue Slightly Misses Forecasts
Freshpet Inc. (NASDAQ:FRPT) shares fell nearly 3% in pre-market trading Monday after the pet food company reported fourth-quarter results that topped profit expectations but came in marginally below revenue forecasts. The company posted adjusted earnings per share of $0.64 for the quarter, exceeding analyst estimates of $0.41 by $0.23. Quarterly revenue totaled $285.2 million, narrowly…
-
GeneDx Posts Mixed Q4 Performance as Earnings Miss but Revenue Tops Estimates
GeneDx Holdings Corp. (NASDAQ:WGS) reported mixed results for the fourth quarter, with earnings falling short of expectations even as revenue came in slightly ahead of analyst forecasts. Shares slipped 0.07% in pre-market trading following the release. The rare disease diagnostics firm reported a quarterly loss of $0.61 per share, well below the analyst consensus, which…
-
A strategically important mineral playing a critical role in clean energy technologies
Hello, I’m Ricki Lee, and this is The Capital Compass. Today we’re looking at Boron One (USOTC:ERVFF) (TSXV:BONE), a company focused on what many consider one of the most strategically important, and often overlooked, industrial minerals in the world: boron. Boron plays a critical role across clean energy technologies, including electric vehicles, solar panels, and…
-
Johnson & Johnson Presents Three-Year TREMFYA Data Showing Sustained Ulcerative Colitis Outcomes
Johnson & Johnson (NYSE:JNJ) reported new long-term data indicating that its therapy TREMFYA (guselkumab) continued to deliver sustained clinical and endoscopic benefits over 140 weeks in adults with moderately to severely active ulcerative colitis. Results from the QUASAR long-term extension study showed that 80.8% of patients treated with TREMFYA achieved clinical remission at week 140.…
-
Faraday Future Plans Initial Robotics Shipments to Start Next Week
Faraday Future Intelligent Electric Inc. (NASDAQ:FFAI) said it will launch its first wave of robotics deliveries next week, according to an update from founder and co-CEO YT Jia. The company stated that certification and regulatory compliance processes have been completed for its Futurist and Master robotic platforms, while approval for the Aegis system is expected…